Prevalence and Spectrum of Second Primary Malignancies among People Living with HIV in the French Dat'AIDS Cohort.
AIDS
AIDS-defining cancers
HIV
cancer survivors
non AIDS-defining cancers
secondary primary cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Jan 2022
13 Jan 2022
Historique:
received:
04
11
2021
revised:
10
01
2022
accepted:
11
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
We aimed to describe the prevalence and spectrum of second primary cancer (SPC) in HIV-positive cancer survivors. A multicenter retrospective study was performed using longitudinal data from the French Dat'AIDS cohort. Subjects who had developed at least two primary cancers were selected. The spectrum of SPCs was stratified by the first primary cancer type and by sex. Among the 44,642 patients in the Dat'AIDS cohort, 4855 were diagnosed with cancer between 1 December 1983 and 31 December 2015, of whom 444 (9.1%) developed at least two primary cancers. The most common SPCs in men were non-Hodgkin lymphoma (NHL) (22.8%), skin carcinoma (10%) and Kaposi sarcoma (KS) (8.4%), and in women the most common SPCs were breast cancer (16%), skin carcinoma (9.3%) and NHL (8%). The pattern of SPCs differed according to first primary cancer and by sex: in men, NHL was the most common SPC after primary KS and KS was the most common SPC after primary NHL; while in women, breast cancer was the most common SPC after primary NHL and primary breast cancer. The frequency and pattern of subsequent cancers among HIV-positive cancer survivors differed according to the first primary cancer type and sex.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to describe the prevalence and spectrum of second primary cancer (SPC) in HIV-positive cancer survivors.
METHODS
METHODS
A multicenter retrospective study was performed using longitudinal data from the French Dat'AIDS cohort. Subjects who had developed at least two primary cancers were selected. The spectrum of SPCs was stratified by the first primary cancer type and by sex.
RESULTS
RESULTS
Among the 44,642 patients in the Dat'AIDS cohort, 4855 were diagnosed with cancer between 1 December 1983 and 31 December 2015, of whom 444 (9.1%) developed at least two primary cancers. The most common SPCs in men were non-Hodgkin lymphoma (NHL) (22.8%), skin carcinoma (10%) and Kaposi sarcoma (KS) (8.4%), and in women the most common SPCs were breast cancer (16%), skin carcinoma (9.3%) and NHL (8%). The pattern of SPCs differed according to first primary cancer and by sex: in men, NHL was the most common SPC after primary KS and KS was the most common SPC after primary NHL; while in women, breast cancer was the most common SPC after primary NHL and primary breast cancer.
CONCLUSION
CONCLUSIONS
The frequency and pattern of subsequent cancers among HIV-positive cancer survivors differed according to the first primary cancer type and sex.
Identifiants
pubmed: 35053563
pii: cancers14020401
doi: 10.3390/cancers14020401
pmc: PMC8773756
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer. 2016 Oct;122(19):3075-86
pubmed: 27377470
CA Cancer J Clin. 2014 Jul-Aug;64(4):225-49
pubmed: 24916760
AIDS. 2020 Jul 1;34(8):1237-1245
pubmed: 32287068
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):554-563
pubmed: 33310788
Curr Opin HIV AIDS. 2017 Jan;12(1):6-11
pubmed: 27749369
BMC Cancer. 2020 Jan 21;20(1):51
pubmed: 31964352
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):1996-2005
pubmed: 21980007
J Hepatol. 2015 Oct;63(4):822-8
pubmed: 25937437
Cancer Causes Control. 2017 Oct;28(10):1065-1074
pubmed: 28900786
Prev Med. 2016 Sep;90:52-8
pubmed: 27370167
BMC Cancer. 2014 Feb 15;14:94
pubmed: 24528929
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):561-70
pubmed: 23535024
PLoS One. 2014 Mar 18;9(3):e92334
pubmed: 24642949
AIDS Care. 2017 Oct;29(10):1235-1242
pubmed: 28610435
Cancer Epidemiol. 2018 Oct;56:97-105
pubmed: 30125884
Bull Cancer. 2021 Oct;108(10):908-914
pubmed: 34452700
Lancet HIV. 2018 Nov;5(11):e647-e655
pubmed: 30245004
Cancer Radiother. 2017 Feb;21(1):10-15
pubmed: 28034681
Cancer Sci. 2014 Jul;105(7):890-6
pubmed: 24814518
J Cancer Res Clin Oncol. 2011 Jan;137(1):115-23
pubmed: 20306087
BMC Cancer. 2009 Oct 20;9:373
pubmed: 19843324
CA Cancer J Clin. 2015 Nov-Dec;65(6):428-55
pubmed: 26348643
Front Public Health. 2017 Jul 21;5:178
pubmed: 28785554
HIV Med. 2017 Mar;18(3):181-195
pubmed: 28967199
Am J Epidemiol. 1994 Feb 15;139(4):362-8
pubmed: 8109570
Lancet HIV. 2017 Nov;4(11):e495-e504
pubmed: 28803888
Sex Transm Infect. 2014 Jun;90(4):337-43
pubmed: 24482488
Ann Intern Med. 2010 Oct 5;153(7):452-60
pubmed: 20921544
JAMA Oncol. 2018 Jan 1;4(1):48-53
pubmed: 28837714
Am Soc Clin Oncol Educ Book. 2014;:e57-67
pubmed: 24857148
Cancer Causes Control. 2011 May;22(5):671-9
pubmed: 21327458
Int J Cancer. 2008 Nov 15;123(10):2390-6
pubmed: 18729183
AIDS Care. 2015;27(10):1220-30
pubmed: 26168817
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):566-71
pubmed: 17372253